Breach of national and EU legislation on drug prices by Greece claimed by pharma trade group

Last week’s meeting of the Greek Pharmaceutical Pricing Committee of the Ministry of Health, which was expected to issue a Corrective Price Bulletin, took the representatives of the pharmaceutical industry by surprise, as once again the Ministry refused to act on the Committee’s recommendation on a correction of all pricing errors, says the Hellenic Association of Pharmaceutical Companies (SfEE).

Although the existing errors have been recognized, they still remain uncorrected, says the SfEE. The Ministry has repeatedly ignored the relevant recommendations and opinions of the Pricing Committee, thereby increasing the risk of supply shortages in the market at the expense of Greek patients. In fact, only certain numerical errors were corrected, while about 600 objections are pending, relating to: